Form 4: Achieve Life Sciences CFO Oki Exercises PRSUs, Sells for Tax

Achieve Life Sciences CFO Mark Oki acquired 168,000 shares through PRSU settlement and sold 50,060 shares to cover tax obligations.

Summary

• Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported transactions on September 18, 2025.
• Oki acquired 168,000 shares of common stock upon the settlement of Performance Restricted Stock Units (PRSUs) at an exercise price of $0.
• Following this acquisition, Oki beneficially owned 178,000 shares directly.
• Concurrently, Oki sold 50,060 shares of common stock to satisfy income tax withholding and remittance obligations related to the PRSU settlement.
• The shares were sold at a weighted average price of $2.92 per share, with individual transactions ranging from $2.83 to $3.02 per share.
• After the sale, Oki's direct beneficial ownership stands at 127,940 shares of common stock.
• The PRSUs, which represented a contingent right to receive one share per unit, vested upon the achievement of certain milestones.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of equity compensation and a subsequent sale to cover tax obligations. This is a neutral event, neither significantly positive nor negative for the company's operational or financial outlook.

Positives

• The settlement of Performance Restricted Stock Units (PRSUs) indicates that performance milestones were met, leading to the vesting of 168,000 shares for the CFO.
• The acquisition of shares, even if partially offset by a tax-related sale, increases the CFO's overall stake in the company from the PRSU award.

Negatives

• A portion of the acquired shares (50,060 shares) was immediately sold to cover tax liabilities, reducing the direct beneficial ownership that would have resulted from the full PRSU settlement.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report (Form 4) detailing compensation-related stock movements for a Chief Financial Officer. It does not provide information directly related to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and is unlikely to have a significant direct impact on the company's share price or fundamental value. It reflects the vesting of previously awarded equity compensation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CFO's Performance Restricted Stock Units vested, leading to an acquisition of shares and a subsequent sale to cover tax obligations. Such transactions are common and do not typically indicate a change in the company's fundamental prospects or warrant an alteration in investment strategy. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to change an existing investment thesis.

Keywords

Achieve Life Sciences, ACHV, Mark Oki, CFO, Form 4, Insider Transaction, Performance Restricted Stock Units, PRSU, Stock Sale, Tax Withholding